Myeloid-derived suppressor cellsa new therapeutic target to overcome resistance to cancer immunotherapy
Myeloid-derived suppressor cellsa new therapeutic target to overcome resistance to cancer immunotherapy
复制标题
DOI：
10.1189/jlb.5vmr1116-458rrr
复制
发表时间：
2017-09-01
影响因子：
5.5
通讯作者：
Yaddanapudi, Kavitha
中科院分区：
文献类型：
--
作者：
Chesney, Jason A.;Mitchell, Robert A.;Yaddanapudi, Kavitha
髓源性抑制细胞（myeloid -derived suppressor cells, MDSCs）是一种异质的未成熟髓细胞群，在癌症等病理条件下积累。被诊断为晚期转移性癌症的患者的平均生存期为12-24个月，在过去的30年里，生存期没有显著变化。尽管接受免疫疗法（如免疫检查点抑制剂）的患者在反应率和总生存率方面有一些令人鼓舞的改善，但大多数患者最终会进展。MDSCs通过积极抑制抗肿瘤T细胞增殖和细胞毒性活性，以及促进致瘤性T调节细胞的扩张，从而抑制宿主对肿瘤的免疫反应，从而促进免疫治疗耐药性。此外，MDSCs促进血管生成、肿瘤侵袭和转移。因此，MDSCs是多种癌症病例的潜在治疗靶点。本文综述了MDSCs的表型和功能特征，并概述了针对MDSCs的单一和组合治疗策略，目的是提高癌症免疫治疗的疗效。
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that accumulate during pathologic conditions, such as cancer. Patients diagnosed with advanced metastatic cancers have an average survival of 12-24 mo, a survival time that hasn't changed significantly in the past 30 yr. Despite some encouraging improvements in response rates and overall survival in patients receiving immunotherapies, such as immune checkpoint inhibitors, most patients will ultimately progress. MDSCs contribute to immunotherapeutic resistance by actively inhibiting antitumor T cell proliferation and cytotoxic activity as well as by promoting expansion of protumorigenic T regulatory cells, thereby, dampening the host immune responses against the tumor. In addition, MDSCs promote angiogenesis, tumor invasion, and metastasis. Thus, MDSCs are potential therapeutic targets in cases of multiple cancers. This review focuses on the phenotypic and functional characteristics of MDSCs and provides an overview of the mono- and combinatorial-therapeutic strategies that target MDSCs with an objective of enhancing the efficacy of cancer immunotherapies.